您的浏览器禁用了JavaScript(一种计算机语言,用以实现您与网页的交互),请解除该禁用,或者联系我们。[港股财报]:三爱健康集团二零二三年中期报告 - 发现报告
当前位置:首页/财报/招股书/报告详情/

三爱健康集团二零二三年中期报告

2023-09-19港股财报秋***
三爱健康集团二零二三年中期报告

01Corporate Information公司資料三愛健康產業集團有限公司 • 二零二三年中期報告BOARD OF DIRECTORSExecutive DirectorsMr. Chen Chengqing Professor Zhang RongqingMr. Gao BoruiMr. Yuan ChaoyangMr. She HaoNon-executive DirectorMr. Xiu YuanIndependent Non-executive DirectorsProfessor Zhu Yi ZhunMr. Khor Khie Liem Alex Mr. Zhang Ruigen COMPANY SECRETARYMs. Li Yuen ShanAUTHORIZED REPRESENTATIVESMr. She HaoMs. Li Yuen ShanAUDIT COMMITTEEMr. Khor Khie Liem Alex (Chairman) Professor Zhu Yi ZhunMr. Zhang Ruigen REMUNERATION COMMITTEEMr. Khor Khie Liem Alex (Chairman) Professor Zhu Yi ZhunMr. Zhang Ruigen Professor Zhang Rongqing董事會執行董事陳成慶先生張榮慶教授高伯瑞先生袁朝陽先生佘昊先生非執行董事修遠先生獨立非執行董事朱依諄教授許麒麟先生張瑞根先生公司秘書李婉珊女士法定代表佘昊先生李婉珊女士審核委員會許麒麟先生(主 席)朱依諄教授張瑞根先生薪酬委員會許麒麟先生(主 席)朱依諄教授張瑞根先生張榮慶教授 02Corporate Information公司資料SANAI HEALTH INDUSTRY GROUP COMPANY LIMITED • Interim Report 2023提名委員會張瑞根先生(主 席)朱依諄教授許麒麟先生張榮慶教授核數師中審眾環(香 港) 會計師事務所有限公司香港法律顧問蕭鎮邦律師行香港中環都爹利街11號律敦治中心律敦治大廈1302–1303及1802室主要往來銀行南洋商業銀行有限公司恒生銀行有限公司中國建設銀行中國工商銀行股份有限公司中信銀行股份有限公司註冊辦事處Grand Pavilion Hibiscus Way802 West Bay RoadP.O. Box 31119KY1-1205Cayman IslandsNOMINATION COMMITTEEMr. Zhang Ruigen (Chairman)Professor Zhu Yi ZhunMr. Khor Khie Liem AlexProfessor Zhang RongqingAUDITORMazars CPA LimitedHONG KONG LEGAL ADVISORRaymond Siu & Lawyers Units 1302–1303 & 1802Ruttonjee HouseRuttonjee Centre11 Duddell StreetCentral, Hong KongPRINCIPAL BANKERSNanyang Commercial Bank LimitedHang Seng Bank LimitedChina Construction BankIndustrial and Commercial Bank of China LimitedChina CITIC Bank Corporation LimitedREGISTERED OFFICEGrand PavilionHibiscus Way802 West Bay RoadP.O. Box 31119KY1-1205Cayman Islands 03Corporate Information公司資料三愛健康產業集團有限公司 • 二零二三年中期報告香港主要營業地點香港九龍觀塘鴻圖道57號南洋廣場7樓5室股份過戶登記處股份過戶登記總處Royal Bank of Canada Trust Company (Cayman) Limited4th Floor, Royal Bank House24 Shedden Road, George TownGrand Cayman KY1-1110Cayman Islands股份過戶登記處香港分處香港中央證券登記有限公司香港灣仔皇后大道東183號合和中心17M樓股份代號1889網址www.1889hk.comPRINCIPAL PLACE OF BUSINESS IN HONG KONGUnit 5, 7/F.Nanyang Plaza57 Hung To RoadKwun TongKowloon, Hong KongSHARE REGISTRARS AND TRANSFER OFFICESPrincipal share registrar and transfer officeRoyal Bank of Canada Trust Company (Cayman) Limited4th Floor, Royal Bank House24 Shedden Road, George TownGrand Cayman KY1-1110Cayman IslandsHong Kong branch share registrar and transfer officeComputershare Hong Kong Investor Services Limited17M FloorHopewell Centre183 Queen’s Road EastWanchai, Hong KongSTOCK CODE1889WEBSITEwww.1889hk.com 04SANAI HEALTH INDUSTRY GROUP COMPANY LIMITED • Interim Report 2023Management Discussion and Analysis管理層討論及分析The board (the “Board”) of directors (the “Directors”) of Sanai Health Industry Group Company Limited (“Sanai Health Industry” or the “Company”) hereby presents the unaudited condensed consolidated financial statements of the Company and its subsidiaries (collectively referred to the “Group”) for the six-month period ended 30 June 2023 (the “Current Period”), together with the comparative figures for the corresponding period in 2022.BUSINESS REVIEWDuring the Current Period, the Group was principally engaged in three businesses: (i) pharmaceutical products business; (ii) finance leasing business; and (iii) genetic testing and molecular diagnostic services. The three business are stated as below:Pharmaceutical Products BusinessSince the successful transfer of the production line of the Group from our 51%-owned subsidiary to our wholly-owned subsidiary in August 2022, the core production centre as well as the exclusive sales channel of the Group’s own developed pharmaceutical products has been kept under control of our wholly-owned subsidiary during the Current Period. As such, the Group has been able to increase its share of profit generated from the sales of this segment as a significant portion of such profit is no longer required to be shared by the non-controlling interests of our 51%-owned subsidiary as in the past years. Given the aforesaid, despite the fact that there has been a very substantial increase in the general cost of traditional Chinese herbal materials in the PRC since the start of the year of 2023 which has inevitably affected the gross profit margin of the sales of our own developed pharmaceutical products in the Current Period, the Group was still able to increase the profit attributable to our shareholders in the Current Period.三愛健康產業集團有限公司(「三愛健康產業」或「本公司」)董事(「董事」)會(「董事會」)謹此提呈本公司及其附屬公司(統稱「本集團」)截至二零二三年六月三十日止六個月期間(「本期間」)的未經審核簡明綜合財務報表, 連同二零二二年同期的比較數字。業務回顧於本期間內,本 集團主要從事三項業務:(i)醫藥產品業務;(ii)融資租賃業務; 及(iii)基因檢測及分子生物診斷服務。 該三項業務載述如下:醫藥產品業務自二零二二年八月本集團成功將生產線從我們擁有51%股權的附屬公司轉移到我們全資擁有的附屬公司起, 核心生產中心以及本集團自主研發醫藥產品的獨家銷售渠道於本期間一直在我們全資擁有的附屬公司控制下。 因此, 由於我們擁有51%股權的附屬公司的非控股權益不再按往年分佔該分部銷售所得的大部分溢利, 故本集團能夠增加分佔有關溢利的份額。 鑑於上文所述, 儘管自二零二三年開始, 中國傳統中藥材的一般成本大幅增加, 不可避免地影響了本期間自主研發醫藥產品的銷售毛利率, 但本集團仍能增加本期間股東應佔溢利。